The American Society of Hematology (ASH) released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and ...
The American Society of Hematology (ASH) released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening disease of ...
AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...
Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...
CLEVELAND, Ohio – First-line treatment with the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone and an alkylating agent (BDex+AA) improves survival in patients ...
LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a ...
Transthyretin-mediated (ATTR) amyloidosis is a multisystem disease caused by the abnormal deposition of misfolded transthyretin protein as amyloid fibrils in various tissues. ATTR amyloidosis presents ...
Editor’s Note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. In an interview for Healio's Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results